Limited-stage diffuse large B-cell lymphoma: current management and challenges by Zhang, X-Y, Collins, GP, Eyre, TA

Impact of intended and relative dose intensity of R‐CHOP in a large, consecutive cohort of elderly diffuse large B‐cell lymphoma patients treated with curative intent: no differenc... by Eyre, TA, Martinez-Calle, N, Hildyard, C, Eyre, DW, Plaschkes, H, Griffith, J, Wolf, J, Fields, P, Gunawan, A, Oliver, R, Djebbari, F, Booth, S, McMillan, A, Fox, CP, Bishton, MJ, Collins, GP, Hatton, CSR

Impact of intended and relative dose intensity of R‐CHOP in a large, consecutive cohort of elderly diffuse large B‐cell lymphoma patients treated with curative intent: no differenc... by Eyre, TA, Martinez-Calle, N, Hildyard, C, Eyre, DW, Plaschkes, H, Griffith, J, Wolf, J, Fields, P, Gunawan, A, Oliver, R, Djebbari, F, Booth, S, McMillan, A, Fox, CP, Bishton, MJ, Collins, GP, Hatton, CSR

Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real‐world intention‐to‐treat analysis by O'Reilly, MA, Wilson, W, Burns, D, Kuhnl, A, Seymour, F, Uttenthal, B, Besley, C, Alajangi, R, Creasey, T, Paneesha, S, Elliot, J, Gonzalez Arias, C, Iyengar, S, Wilson, MR, Delaney, A, Rubio, L, Lambert, J, Begg, K, Boyle, S, Cheok, KPL, Collins, GP, Roddie, C, Johnson, R, Sanderson, R